News | July 04, 2025
argenx advances clinical development of agonist antibody for myasthenic syndromes
ARGX-119 is the sixth molecule developed through our Immunology Innovation Program to show proof-of-concept
ARGX-119 is the sixth molecule developed through our Immunology Innovation Program to show proof-of-concept
Opaganib has shown potential in enhancing ARPI treatment by blocking multiple enzymes involved in cancer cell survival.
Enhance strategies to drive sustainability, global Reach and digital transformation for a trillion-dollar future
Treatment with XPro was well-tolerated and safe, even in the high risk ApoE4+/+ patient group, and ARIA-E or ARIA-H was not observed in any patients
The collaboration aims to enhance the accuracy of physics-based methods with AI models for optimising small molecule medicine discovery and development
Over 100 million cartridges of rh-insulin supplied to Malaysian health ministry; 345,000+ patients served
The pet dog population alone is expected to increase from 21.4 million in 2019 to 51.5 million by 2028
Label updates reflect growing body of real-world evidence and regulatory confidence in the safety profile of the class of CD19- and BCMA-directed autologous CAR T cell therapies, reinforcing efforts to increase equitable access
Review will evaluate effectiveness in treating alcohol withdrawal syndrome and supporting abstinence, as well as measures to mitigate risk of abuse
The company's decision to withdraw the MAA was due to the timing of the availability of Chemistry Manufacturing and Controls
Subscribe To Our Newsletter & Stay Updated
